{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:04:37Z","timestamp":1790964277721,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K07653"],"award-info":[{"award-number":["19K07653"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA197603"],"award-info":[{"award-number":["R35CA197603"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.omto.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T10:31:17Z","timestamp":1663929077000},"page":"315-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3586-3976","authenticated-orcid":false,"given":"Shin-ichiro","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyotaka","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Iyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Sanpei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00f6rrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Mojsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Nagamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2022.09.001_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-065X.2010.00979.x","article-title":"Therapeutic cancer vaccines: are we there yet?","volume":"239","author":"Klebanoff","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omto.2022.09.001_bib2","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2017-11-785873","article-title":"Vaccine therapy in hematologic malignancies","volume":"131","author":"Avigan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.09.001_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.immuni.2008.08.001","article-title":"Dendritic cells in\u00a0vivo: a key target for a new vaccine science","volume":"29","author":"Steinman","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2022.09.001_bib4","doi-asserted-by":"crossref","first-page":"232ra251","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omto.2022.09.001_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.it.2019.09.008","article-title":"Immune networks and therapeutic targeting of iNKT cells in cancer","volume":"40","author":"Fujii","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","article-title":"Tissue-specific functions of invariant natural killer T\u00a0cells","volume":"18","author":"Crosby","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib8","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.4049\/jimmunol.178.5.2853","article-title":"Tumor cells loaded with \u03b1-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice","volume":"178","author":"Shimizu","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib9","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20070458","article-title":"Cross-presentation of glycolipid from tumor cells loaded with \u03b1-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells","volume":"204","author":"Shimizu","year":"2007","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","article-title":"A phase I-II study of \u03b1-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer","volume":"182","author":"Motohashi","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib11","doi-asserted-by":"crossref","first-page":"e000316","DOI":"10.1136\/jitc-2019-000316","article-title":"Phase II study of alpha-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer","volume":"8","author":"Toyoda","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2022.09.001_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1084\/jem.20011889","article-title":"Natural killer T\u00a0cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines","volume":"195","author":"Gonzalez-Aseguinolaza","year":"2002","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by \u03b1-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib14","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1084\/jem.20040317","article-title":"The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80\/86 costimulation","volume":"199","author":"Fujii","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib15","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.171.10.5140","article-title":"NKT cells enhance CD4+ and CD8+ T\u00a0cell responses to soluble antigen in\u00a0vivo through direct interaction with dendritic cells","volume":"171","author":"Hermans","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00262-017-2085-9","article-title":"A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and alpha-galactosylceramide: induction of polyfunctional T\u00a0cells in high-risk melanoma patients","volume":"67","author":"Gasser","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2022.09.001_bib17","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3389\/fimmu.2020.02043","article-title":"Targeted Co-delivery of tumor antigen and alpha-galactosylceramide to CD141(+) dendritic cells induces a potent tumor antigen-specific human CD8(+) T\u00a0cell response in human immune system mice","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib18","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2008-08-176446","article-title":"Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity","volume":"113","author":"Fujii","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.09.001_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/0008-5472.CAN-12-0759","article-title":"Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in\u00a0situ immune responses by dendritic cells","volume":"73","author":"Shimizu","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.09.001_bib20","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1158\/0008-5472.CAN-15-3219","article-title":"Systemic DC activation modulates the tumor microenvironment and shapes the long-lived tumor-specific memory mediated by CD8+ T\u00a0cells","volume":"76","author":"Shimizu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.omto.2022.09.001_bib21","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.4049\/jimmunol.1300033","article-title":"Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T\u00a0cell induction","volume":"190","author":"Shimizu","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2020.08.019","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2022.09.001_bib23","doi-asserted-by":"crossref","first-page":"140179","DOI":"10.1172\/jci.insight.140179","article-title":"Risk-associated alterations in marrow T\u00a0cells in pediatric leukemia","volume":"5","author":"Bailur","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omto.2022.09.001_bib24","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.09.001_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17474086.2019.1593824","article-title":"What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia","volume":"12","author":"Nakata","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.omto.2022.09.001_bib26","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.09.001_bib28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.09.001_bib30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.blre.2018.03.006","article-title":"Time to repeal and replace response criteria for acute myeloid leukemia?","volume":"32","author":"Bloomfield","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.omto.2022.09.001_bib31","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T\u00a0cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2022.09.001_bib33","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.09.001_bib34","first-page":"124","article-title":"Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study","volume":"10","author":"Brandwein","year":"2020","journal-title":"Am. J. Blood Res."},{"key":"10.1016\/j.omto.2022.09.001_bib35","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2019-128958","article-title":"Outcomes of patients with relapsed or refractory acute myeloid leukemia receiving hypomethylating agent and venetoclax","volume":"134","author":"Asghari","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omto.2022.09.001_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","article-title":"Global characterization of T\u00a0cells in non-small-cell lung cancer by single-cell sequencing","volume":"24","author":"Guo","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8(+) T\u00a0cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2022.09.001_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","article-title":"Precursor exhausted T\u00a0cells: key to successful immunotherapy?","volume":"20","author":"Kallies","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib39","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3389\/fimmu.2018.01884","article-title":"Insights into the molecular mechanisms of T follicular helper-mediated immunity and pathology","volume":"9","author":"Qin","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib40","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.15252\/embj.201490786","article-title":"Molecular profiling of CD8 T\u00a0cells in autochthonous melanoma identifies Maf as driver of exhaustion","volume":"34","author":"Giordano","year":"2015","journal-title":"EMBO J."},{"key":"10.1016\/j.omto.2022.09.001_bib41","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omto.2022.09.001_bib42","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.09.001_bib43","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T\u00a0cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omto.2022.09.001_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T\u00a0cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omto.2022.09.001_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T\u00a0cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2022.09.001_bib46","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-Centered transcriptional network drives an effector versus exhausted CD8 T\u00a0cell-Fate Decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2022.09.001_bib47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T\u00a0cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2022.09.001_bib48","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.celrep.2018.01.072","article-title":"Suppression of Tcf1 by inflammatory cytokines facilitates effector CD8 T\u00a0cell differentiation","volume":"22","author":"Danilo","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omto.2022.09.001_bib49","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T\u00a0cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2022.09.001_bib50","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","article-title":"CD103(+) tumor-resident CD8(+) T\u00a0cells are associated with improved survival in immunotherapy-Naive melanoma patients and expand significantly during anti-PD-1 treatment","volume":"24","author":"Edwards","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2022.09.001_bib51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-1759(02)00497-0","article-title":"Detection and activation of human V\u03b124+ natural killer T cells using \u03b1-galactosyl ceramide-pulsed dendritic cells","volume":"272","author":"Fujii","year":"2003","journal-title":"J.\u00a0Immunol. Methods"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770522001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:23:46Z","timestamp":1762496626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770522001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":51,"alternative-id":["S2372770522001085"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2022.09.001","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}